查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1806348

抗癌藥物市場按藥物類型、給藥途徑、治療類型、癌症類型、最終用戶和分銷管道分類－2025-2030 年全球預測

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年抗癌藥物市場規模將達1,571億美元，2025年成長至1,720.6億美元，複合年成長率為9.81%，2030年將達2,754.8億美元。

主要市場統計數據
基準年2024年 1571億美元
預計2025年 1720.6億美元
預測年份 2030 2754.8億美元
複合年成長率（%） 9.81%

透過揭示根本促進因素、新興創新和戰略產業要求，為癌症藥物分析奠定基礎

抗癌藥物研發的複雜性需要一篇有理有據的導言，概述塑造癌症治療領域的基本力量。細緻入微地理解過去的突破，對於解讀化療、標靶治療和免疫調節劑領域的持續進展至關重要。本文將借鏡歷史里程碑，闡明增加的研究資金、拓展的監管途徑以及以病人為中心的醫療模式如何影響當代的優先事項。

引領由技術突破和不斷發展的患者照護模式推動的腫瘤藥物開發的重大轉變

過去十年，在免疫腫瘤學和分子標靶治療領域取得突破的推動下，一場變革性變革重新定義了腫瘤治療方法模式。查核點抑制劑重塑了多種癌症的治療流程方案，並促使閾值治療和組合方案的重新設計。同時，嵌合體抗原受體T細胞療法已從實驗性治療方法邁向商業性化，預示著個人化免疫療法新時代的到來。

評估美國新徵收的關稅對抗癌藥物供應鏈、定價動態和國際競爭平衡的影響

美國將於2025年初實施新的關稅，這將為腫瘤學價值鏈上的相關人員帶來巨大阻力。採購和分銷合作夥伴面臨著從全球供應商採購關鍵活性藥物原料藥的成本上漲，這促使他們重新評估其生產佈局。近幾個月來，一些公司採取了應對措施，包括多元化供應商、投資近岸外包以及重新談判長期契約，以減輕關稅的影響並確保藥品供應的不間斷。

揭示藥物類別、給藥途徑、治療方式、癌症適應症、最終用戶概況和分銷網路的關鍵細分洞察

透過分析每個藥物類別及其各自的子類別，可以清楚地洞察癌症治療市場。化療仍然是主要的治療方法，烷化劑、抗代謝藥物和抗腫瘤抗生素在根除腫瘤方面表現出不同的療效和安全性。除了傳統的細胞毒性療法外，免疫療法還引入了查核點抑制劑和CAR-T療法，每種療法都需要專門的給藥方案和患者監測。

探索美洲、歐洲、中東和非洲以及亞太地區的區域動態和有效的市場驅動力

區域環境透過醫療基礎設施、法規環境和報銷機制的差異，影響抗癌藥物的部署和採用。在美洲，成熟的專科藥房網路與領先的研究中心相輔相成，促進了先進療法的積極應用。北美的卓越中心正在與付款人合作，制定創新的報銷方案，以降低前期成本並將療效與價值掛鉤。

揭示塑造癌症治療生態系統的主要企業的策略性舉措、合作和創新組合

主要產業參與者正在重新調整其策略重點，以適應不斷發展的癌症治療格局。領先的創新企業正在透過投資早期發現計畫和後期臨床試驗並多元化其投資組合來拓展廣泛的免疫腫瘤學產品線。生技公司與大型製藥企業之間的發展正在加速，這使得能夠達成再授權和共同開發契約授權合約，從而分散風險並利用互補的專業知識。

為行業領導者提供策略要點和實用建議，以利用新的商業機會並應對日益複雜的腫瘤市場

產業領導者應優先考慮整合研發框架，將發現、轉化研究和臨床應用連接起來，以加速從概念到商業化的進程。建立跨職能的卓越中心，整合藥物化學、生物標記分析和監管專業知識，可以簡化決策流程並縮短開發時間。同時，與診斷供應商建立策略聯盟，可以共同開發伴隨檢測，從而增強個人化治療通訊協定。

全面闡述支持腫瘤藥物研究的嚴格調查方法、資料收集通訊協定和分析框架

本研究採用多維度的方法，結合深入的二手資料研究、一手專家訪談和嚴格的資料三角檢驗，確保分析的穩健性。對同行評審期刊、監管指南和臨床試驗註冊庫的廣泛文獻綜述，為理解治療進展提供了基礎。同時，本研究也分析了專有資料庫和產業出版刊物，以了解競爭和專利格局。

整合核心發現、對產業的影響、持續推進抗癌藥物創新的觀點

綜合來看，主要研究結果表明，免疫腫瘤學、精準醫療工具以及數位健康融合領域的突破正在重新定義癌症治療的範式。新貿易政策的累積影響凸顯了建構韌性供應鏈和創新報銷策略的必要性，以保障患者獲得治療並實現商業性可行性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 將CAR-T細胞療法拓展至固態腫瘤早期治療
  • 以生物標記為重點的監管核准正在推動腫瘤無關治療方法的成長
  • 透過整合人工智慧驅動的診斷平台最佳化個人化癌症藥物選擇
  • 增加對口服溶瘤藥物的投資，用於晚期癌症患者的慢性治療
  • 免疫療法與標靶小分子結合的聯合治療激增
  • 利用液態生物檢體引導的治療監測加速精準腫瘤學
  • 具有新型細胞毒性有效載荷的新一代抗體藥物偶聯物的出現
  • 生技公司與大型製藥公司進行策略合作，快速開發腫瘤學產品線
  • 促進孤兒藥途徑中孤兒藥開發的監管獎勵
  • 採用真實世界證據支持上市後監測和附加檔擴展

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章：抗癌藥物市場（依藥物類型）

  • 化療
    • 烷化劑
    • 抗代謝藥
    • 抗腫瘤抗生素
  • 荷爾蒙療法
  • 免疫療法
  • 標靶治療
    • 誘導凋亡藥物
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑（TKI）

第9章：抗癌藥物市場（依給藥途徑）

  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下

第 10 章：抗癌藥物市場（依治療類型）

  • 聯合治療
  • 單藥治療

第11章 抗癌藥物市場（以癌症類型）

  • 乳癌
  • 大腸直腸癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 攝護腺癌

第 12 章：抗癌藥物市場（以最終用戶分類）

  • 門診治療中心
  • 家庭醫療保健
  • 醫院和診所

第 13 章：抗癌藥物市場（依分銷管道）

  • 醫院藥房
  • 零售藥局

第 14 章：美洲抗癌藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第15章歐洲、中東和非洲抗癌藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第16章：亞太地區抗癌藥物市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • Astellas Pharma Inc
    • AstraZeneca PLC
    • Bayer AG
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Fresenius Kabi AG
    • Getwell Oncology Pvt Ltd
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Kite Pharma, Inc by Gilead Company
    • Medivir AB
    • Merck & Co., Inc.
    • Nammi Therapeutics, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
    • Takeda Pharmaceutical Company Limited

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 157.10 billion in 2024 and is projected to grow to USD 172.06 billion in 2025, with a CAGR of 9.81%, reaching USD 275.48 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 157.10 billion
Estimated Year [2025] USD 172.06 billion
Forecast Year [2030] USD 275.48 billion
CAGR (%) 9.81%

Establishing the Foundation of Cancer Drug Analysis by Highlighting Fundamental Drivers, Emerging Innovations, and Strategic Industry Imperatives

The complexity of cancer drug development demands a well-grounded introduction that outlines the fundamental forces shaping the oncology therapeutic sphere. A nuanced understanding of past breakthroughs provides essential context for interpreting ongoing advancements in chemotherapies, targeted approaches, and immunomodulatory agents. Building from historical milestones, this introduction illuminates how intensified research funding, expanded regulatory pathways, and patient-centric care models converge to influence contemporary priorities.

Moreover, rapid technological evolution in molecular diagnostics and biomarker discovery has created new opportunities for precision oncology, driving collaboration among academic institutions, biotech startups, and established pharmaceutical developers. In this light, the introduction establishes a framework for how shifting regulatory paradigms-such as accelerated approval programs and adaptive licensing-facilitate the entry of innovative compounds while ensuring patient safety.

By setting the stage with key research enablers, stakeholder motivations, and cross-sector partnerships, this section underscores the dynamic environment in which oncology stakeholders operate. It paves the way for subsequent analysis of disruptive trends and market-shaping events, providing readers with a cohesive starting point to appreciate the deeper insights that follow.

Navigating the Pivotal Transformations in Oncology Drug Development Driven by Technological Breakthroughs and Evolving Patient Care Paradigms

Over the past decade, transformative shifts have redefined the oncology therapeutics landscape, driven by breakthroughs in immuno-oncology and molecularly targeted treatments. Checkpoint inhibitors have reshaped therapeutic algorithms across multiple cancer types, prompting redesigns of standard of care and combination regimens. Simultaneously, chimeric antigen receptor T cell therapies have crossed thresholds from experimental modalities to commercial realities, heralding a new era of personalized immunotherapy.

In parallel, the convergence of big data analytics and precision medicine tools has accelerated the identification of patient subpopulations most likely to benefit from specific interventions. This evolution has compelled industry leaders to integrate companion diagnostics into clinical development plans, fostering collaborative models between diagnostic and therapeutic stakeholders. Moreover, digital health platforms now support remote monitoring and real-time outcome tracking, enhancing trial efficiency and enabling adaptive trial designs that reduce development timelines.

As regulatory bodies refine frameworks for advanced therapies, the industry adapts by forging strategic alliances, expanding manufacturing capabilities, and integrating artificial intelligence for compound discovery. These advances underscore an ongoing paradigm shift that elevates efficacy, safety, and patient-centricity at the heart of oncology R&D.

Assessing the Ramifications of Newly Implemented United States Tariffs on Cancer Drug Supply Chains, Pricing Dynamics, and Global Competitive Equilibrium

The implementation of new United States tariffs in early 2025 has introduced significant headwinds for stakeholders across the cancer drug value chain. Procurement and distribution partners are facing increased costs for critical active pharmaceutical ingredients sourced from global suppliers, prompting a reassessment of manufacturing footprints. In recent months, several organizations have responded by diversifying supplier bases, investing in nearshoring initiatives, and renegotiating long-term contracts to mitigate tariff exposure and secure uninterrupted drug availability.

Furthermore, heightened import duties on specialized components have compelled pharmaceutical companies to adjust pricing frameworks, which in turn places pressure on reimbursement dialogues with payers. Payer panels and health technology assessment bodies are closely monitoring these cost adjustments, leading some manufacturers to pursue risk-sharing agreements and performance-based contracts to sustain market access.

Transitioning beyond immediate cost considerations, industry participants are also reevaluating supply chain resilience by integrating advanced analytics for demand forecasting and inventory management. These strategic shifts underscore the multifaceted impact of tariff introductions, demonstrating how regulatory trade actions can cascade through production, pricing, and patient access, ultimately reshaping competitive dynamics in oncology drug markets.

Unraveling Critical Segmentation Insights across Drug Classes, Administration Pathways, Therapy Modalities, Cancer Indications, End User Profiles, and Distribution Networks

Insight into the oncology drug market emerges clearly when dissecting therapeutic classes alongside their respective subcategories. Chemotherapy remains a cornerstone modality, with alkylating agents, antimetabolites, and antitumor antibiotics demonstrating differentiated efficacy profiles and safety considerations in tumor eradication. Beyond traditional cytotoxics, the immunotherapy cohort has introduced checkpoint inhibitors and CAR-T treatments, each requiring specialized administration protocols and patient monitoring.

Administration routes further refine market understanding by highlighting patient convenience and adherence factors. Intravenous infusions dominate hospital settings, whereas oral formulations offer greater flexibility for outpatient management and home healthcare delivery. Intramuscular and subcutaneous injections occupy niche roles in maintenance therapies and prophylactic regimens, reflecting a balance between therapeutic intent and patient experience.

Therapy type segmentation, distinguishing combination regimens from monotherapy approaches, reveals evolving clinical strategies aimed at overcoming resistance and enhancing synergistic effects. Cancer type delineation uncovers unique demand patterns across breast, colorectal, liver, lung, pancreatic, and prostate cancer cohorts, each presenting distinct molecular targets and treatment pathways.

End user segmentation clarifies distribution of care delivery, from hospitals and clinics as centralized hubs to ambulatory care centers and home healthcare solutions that prioritize patient comfort. Distribution channel analysis underscores the roles of hospital pharmacies in inpatient settings and retail pharmacies in broadening access for maintenance therapies.

Exploring Regional Dynamics and Differentiated Market Drivers across the Americas, Europe Middle East and Africa, and the Asia Pacific Oncology Landscapes

Regional landscapes shape the deployment and adoption of cancer therapeutics through variations in healthcare infrastructure, regulatory environments, and reimbursement mechanisms. In the Americas, well-established specialty pharmacy networks complement leading research centers, driving robust uptake of advanced therapies. North American centers of excellence collaborate with payers to structure innovative reimbursement schemes that mitigate upfront costs and link outcomes to value.

Moving eastward, the Europe, Middle East, and Africa region presents a tapestry of regulatory frameworks. While Western European nations lean on centralized approval pathways and stringent health technology assessments, Middle Eastern markets are investing heavily in oncology infrastructure and forging public-private partnerships to expand access. African markets continue to build foundational oncology programs, with an increasing focus on affordable generics and biosimilars to bridge treatment gaps.

Across the Asia-Pacific domain, diverse economies drive heterogenous demand patterns. Advanced markets such as Japan and Australia leverage strong R&D ecosystems and integrated care models, while emerging economies prioritize capacity building in oncology centers and localization of manufacturing. Regional harmonization efforts aim to streamline regulatory submissions, accelerating the entry of novel agents into clinical practice and supporting patient-centric care models.

Illuminating Strategic Moves, Collaborative Endeavors, and Innovation Portfolios of Leading Entities Shaping the Cancer Therapeutics Ecosystem

Key industry participants have recalibrated their strategic priorities to align with the evolving oncology therapeutic environment. Leading innovators have pursued expansive immuno-oncology pipelines, investing in both early-stage discovery programs and late-stage clinical trials to diversify their portfolios. Collaboration between biotechs and major pharmaceutical firms has accelerated, enabling sublicensing deals and co-development agreements that distribute risk and leverage complementary expertise.

Manufacturers with robust biologics infrastructure are expanding capacity for cell and gene therapies, preempting anticipated manufacturing bottlenecks. Simultaneously, the emergence of digital health partnerships has allowed select companies to integrate real-world evidence collection into their launch strategies, enhancing post-market value propositions. Players with global regulatory experience are optimizing dossier submissions to navigate complex approval pathways, particularly in regions adopting novel regulatory paradigms.

Smaller specialized firms are capitalizing on niche targets, forging alliances to secure co-marketing opportunities and expand trial networks. Across the competitive landscape, agility and scientific differentiation have emerged as critical differentiators, enabling companies to position their assets effectively against established standards of care and pipeline entrants.

Strategic Imperatives and Pragmatic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Oncology Market Complexities

Industry leaders should prioritize integrated R&D frameworks that bridge discovery, translational research, and clinical application to accelerate the path from concept to commercialization. Establishing cross-functional centers of excellence that coalesce medicinal chemistry, biomarker analytics, and regulatory expertise can streamline decision making and reduce development timelines. In parallel, forging strategic alliances with diagnostics providers will enable the co-development of companion assays that bolster personalized treatment protocols.

To mitigate supply chain vulnerabilities exposed by recent trade policy shifts, organizations must diversify sourcing strategies and invest in advanced supply planning platforms. Scenario modeling and digital twins for logistics networks can empower procurement teams to anticipate disruptions and maintain consistent access to high-value active pharmaceutical ingredients. Moreover, engaging payers early to define outcome-based reimbursement frameworks will align commercial strategies with therapeutic value and ensure sustained market access.

Finally, embedding patient-centricity through digital support services and telehealth integration can enhance adherence, real-world data capture, and long-term outcomes tracking. By adopting these recommendations, industry players can fortify their competitive positioning and lead in delivering next-generation oncology treatments.

Comprehensive Elucidation of Rigorous Research Methodologies, Data Collection Protocols, and Analytical Frameworks Underpinning the Oncology Drug Study

This research employs a multifaceted methodology that integrates exhaustive secondary research, primary expert interviews, and rigorous data triangulation to ensure analytical robustness. Extensive literature reviews of peer-reviewed journals, regulatory guidelines, and clinical trial registries provided a foundational understanding of therapeutic advancements. Concurrently, proprietary databases and industry publications were analyzed to map competitive activity and patent landscapes.

Primary insights were garnered through structured interviews with senior executives, clinical investigators, and reimbursement specialists, yielding firsthand perspectives on pipeline strategies, market access barriers, and patient needs. Quantitative and qualitative findings were cross-validated through triangulation techniques, ensuring consistency across data sources and minimizing bias.

Furthermore, the study incorporated scenario analyses to examine the impact of policy shifts, such as tariff implementations, on production and distribution dynamics. Ethical adherence to data privacy and confidentiality standards was maintained throughout. The resulting framework synthesizes complex inputs into a coherent narrative, furnishing stakeholders with actionable intelligence underpinned by transparent methodologies.

Synthesis of Core Findings, Industry Implications, and Forward-Looking Perspectives to Propel Continued Advancements in Cancer Drug Innovation

In synthesizing the core findings, the review underscores how immuno-oncology breakthroughs, precision medicine tools, and digital health integrations collectively redefine the cancer treatment paradigm. The cumulative effects of new trade policies highlight the necessity for resilient supply chains and innovative reimbursement strategies to preserve patient access and commercial viability.

Segmentation analyses clarify nuanced demand drivers across therapeutic classes, administration modes, and care settings, while regional insights reveal differentiated growth enablers shaped by regulatory and infrastructure variances. The competitive landscape analysis illustrates that collaborative alliances and agile portfolio management are essential for maintaining differentiation in a crowded pipeline.

Looking forward, the interplay between scientific innovation, regulatory evolution, and patient-centric frameworks promises to sustain momentum in oncology drug development. Stakeholders who embrace integrated research models, engage with payers on value-based approaches, and invest in resilient operational infrastructures will be best positioned to deliver transformative therapies and secure long-term market leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of CAR T-cell therapies into earlier lines of treatment for solid tumors
  • 5.2. Growth of tumor-agnostic therapies driven by biomarker-focused regulatory approvals
  • 5.3. Integration of AI-driven diagnostic platforms to optimize personalized cancer drug selection
  • 5.4. Rising investment in oral oncolytics for chronic management of advanced cancer patients
  • 5.5. Surge in combination regimens pairing immunotherapy with targeted small molecules
  • 5.6. Acceleration of precision oncology through liquid biopsy-guided treatment monitoring
  • 5.7. Emergence of next-generation antibody-drug conjugates with novel cytotoxic payloads
  • 5.8. Strategic partnerships between biotech and big pharma to fast-track oncology pipelines
  • 5.9. Regulatory incentives fueling development of rare cancer drugs under orphan drug pathways
  • 5.10. Adoption of real-world evidence to support post-market surveillance and label expansions

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cancer Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Chemotherapy
    • 8.2.1. Alkylating Agents
    • 8.2.2. Antimetabolites
    • 8.2.3. Antitumor Antibiotics
  • 8.3. Hormone Therapy
  • 8.4. Immunotherapy
  • 8.5. Targeted Therapy
    • 8.5.1. Apoptosis-inducing Drugs
    • 8.5.2. Monoclonal Antibodies
    • 8.5.3. Tyrosine Kinase Inhibitors (TKIs)

9. Cancer Drugs Market, by Administration Route

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intravenous
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Cancer Drugs Market, by Therapy Type

  • 10.1. Introduction
  • 10.2. Combination Therapy
  • 10.3. Monotherapy

11. Cancer Drugs Market, by Cancer Type

  • 11.1. Introduction
  • 11.2. Breast Cancer
  • 11.3. Colorectal Cancer
  • 11.4. Liver Cancer
  • 11.5. Lung Cancer
  • 11.6. Pancreatic Cancer
  • 11.7. Prostate Cancer

12. Cancer Drugs Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Home Healthcare
  • 12.4. Hospitals & Clinics

13. Cancer Drugs Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Retail Pharmacy

14. Americas Cancer Drugs Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Cancer Drugs Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Cancer Drugs Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Amgen Inc.
    • 17.3.3. Astellas Pharma Inc
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Bayer AG
    • 17.3.6. BeiGene, Ltd.
    • 17.3.7. Bristol-Myers Squibb Company
    • 17.3.8. Daiichi Sankyo Company, Limited
    • 17.3.9. Dr. Reddy's Laboratories Ltd.
    • 17.3.10. Eli Lilly and Company
    • 17.3.11. F. Hoffmann-La Roche Ltd
    • 17.3.12. Fresenius Kabi AG
    • 17.3.13. Getwell Oncology Pvt Ltd
    • 17.3.14. GlaxoSmithKline plc
    • 17.3.15. Incyte Corporation
    • 17.3.16. Kite Pharma, Inc by Gilead Company
    • 17.3.17. Medivir AB
    • 17.3.18. Merck & Co., Inc.
    • 17.3.19. Nammi Therapeutics, Inc.
    • 17.3.20. Novartis AG
    • 17.3.21. Pfizer Inc.
    • 17.3.22. Sanofi S.A.
    • 17.3.23. Sun Pharmaceutical Industries Ltd.
    • 17.3.24. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
    • 17.3.25. Takeda Pharmaceutical Company Limited

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. CANCER DRUGS MARKET: RESEARCHAI
  • FIGURE 28. CANCER DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. CANCER DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 30. CANCER DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 161. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 162. BRAZIL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. ARGENTINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. ARGENTINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 213. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GERMANY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. GERMANY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 217. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. GERMANY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. GERMANY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 229. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. FRANCE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 233. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. FRANCE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 235. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 236. FRANCE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 243. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. FRANCE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 245. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. RUSSIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. RUSSIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 249. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. RUSSIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 251. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 252. RUSSIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 253. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. RUSSIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 259. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. RUSSIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 261. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ITALY CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. ITALY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 265. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 267. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 268. ITALY CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 269. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ITALY CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 271. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. ITALY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ITALY CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 275. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. ITALY CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 277. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. SPAIN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. SPAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 281. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. SPAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 283. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 284. SPAIN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 285. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 330. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 341. DENMARK CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. DENMARK CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 343. DENMARK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 344. DENMARK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 345. DENMARK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 346. DENMARK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
  • TABLE 347. DENMARK CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 348. DENMARK CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
  • TABLE 349. DENMARK CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. DENMARK CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 351. DENMARK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. DENMARK CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 353. DENMARK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. DENMARK CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 355. DENMARK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 356. DENMARK CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 357. NETHERLANDS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. NETHERLANDS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 359. NETHERLANDS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 360. NETHERLANDS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
  • TABLE 361. NETHER